Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic.


Journal

Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562

Informations de publication

Date de publication:
06 2022
Historique:
received: 21 12 2021
accepted: 27 04 2022
revised: 26 04 2022
pubmed: 8 5 2022
medline: 15 6 2022
entrez: 7 5 2022
Statut: ppublish

Résumé

WD repeat domain 5 (WDR5), an integral component of the MLL/KMT2A lysine methyltransferase complex, is critically involved in oncogenesis and represents an attractive onco-target. Inhibitors targeting protein-protein interactions (PPIs) between WDR5 and its binding partners, however, do not inhibit all of WDR5-mediated oncogenic functions and exert rather limited antitumor effects. Here, we report a cereblon (CRBN)-recruiting proteolysis targeting chimera (PROTAC) of WDR5, MS40, which selectively degrades WDR5 and the well-established neo-substrates of immunomodulatory drugs (IMiDs):CRBN, the Ikaros zinc finger (IKZF) transcription factors IKZF1 and IKZF3. MS40-induced WDR5 degradation caused disassociation of the MLL/KMT2A complex off chromatin, resulting in decreased H3K4me2. Transcriptomic profiling revealed that targets of both WDR5 and IMiDs:CRBN were significantly repressed by treatment of MS40. In MLL-rearranged leukemias, which exhibit IKZF1 high expression and dependency, co-suppression of WDR5 and Ikaros by MS40 is superior in suppressing oncogenesis to the WDR5 PPI inhibitor, to MS40's non-PROTAC analog controls (MS40N1 and MS40N2, which do not bind CRBN and WDR5, respectively), and to a matched VHL-based WDR5 PROTAC (MS169, which degrades WDR5 but not Ikaros). MS40 suppressed the growth of primary leukemia patient cells in vitro and patient-derived xenografts in vivo. Thus, dual degradation of WDR5 and Ikaros is a promising anti-cancer strategy.

Identifiants

pubmed: 35525905
doi: 10.1038/s41388-022-02340-8
pii: 10.1038/s41388-022-02340-8
pmc: PMC9189076
mid: NIHMS1805493
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Antineoplastic Agents 0
Ikaros Transcription Factor 148971-36-2
IKZF1 protein, human 0
Intracellular Signaling Peptides and Proteins 0
Ubiquitin-Protein Ligases EC 2.3.2.27
WDR5 protein, human 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3328-3340

Subventions

Organisme : NCI NIH HHS
ID : R01 CA211336
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA268384
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA236209
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM122749
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM121293
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA217297
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA215284
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA262903
Pays : United States
Organisme : NIH HHS
ID : S10 OD028504
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016086
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103429
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM137009
Pays : United States
Organisme : NIH HHS
ID : S10 OD025132
Pays : United States
Organisme : NIGMS NIH HHS
ID : R35 GM131780
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA196521
Pays : United States
Organisme : NIGMS NIH HHS
ID : R24 GM137786
Pays : United States
Organisme : NIH HHS
ID : S10 OD018445
Pays : United States

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Références

Nature. 2015 Sep 10;525(7568):206-11
pubmed: 26331536
Nat Chem Biol. 2015 Aug;11(8):571-578
pubmed: 26167872
Nat Struct Mol Biol. 2009 Jul;16(7):678-80
pubmed: 19578375
J Biol Chem. 2010 Oct 22;285(43):32967-32976
pubmed: 20716525
Nat Rev Cancer. 2021 Jul;21(7):413-430
pubmed: 34002060
Nature. 2015 Jul 9;523(7559):183-188
pubmed: 26131937
ACS Med Chem Lett. 2013 Feb 04;4(3):353-7
pubmed: 24900672
Nature. 2021 Jul;595(7868):591-595
pubmed: 34163069
Eur J Med Chem. 2016 Nov 29;124:480-489
pubmed: 27598236
J Biol Chem. 2018 Apr 20;293(16):6187-6200
pubmed: 29449372
J Biol Chem. 2016 Oct 21;291(43):22357-22372
pubmed: 27563068
Cancer Res. 2015 Dec 1;75(23):5143-54
pubmed: 26471359
Cell Discov. 2016 May 17;2:16008
pubmed: 27462455
J Biol Chem. 2011 Feb 4;286(5):3359-69
pubmed: 21106533
Cancer Cell. 2016 Jul 11;30(1):92-107
pubmed: 27344947
Cell Rep. 2016 Jun 28;16(1):133-147
pubmed: 27320920
Nat Chem Biol. 2014 Apr;10(4):305-12
pubmed: 24584101
Nat Rev Drug Discov. 2017 Feb;16(2):101-114
pubmed: 27885283
Nat Commun. 2021 Feb 16;12(1):1045
pubmed: 33594072
Sci Transl Med. 2021 Sep 29;13(613):eabj1578
pubmed: 34586829
Blood. 2019 Oct 3;134(14):1176-1189
pubmed: 31383640
Blood. 2015 Jan 8;125(2):346-57
pubmed: 25395428
Front Mol Biosci. 2021 Dec 07;8:788440
pubmed: 34950704
J Clin Med. 2018 Jan 30;7(2):
pubmed: 29385767
Cancer Cell. 2016 Apr 11;29(4):574-586
pubmed: 27070704
J Med Chem. 2018 Jul 12;61(13):5623-5642
pubmed: 29889518
J Med Chem. 2021 Aug 12;64(15):10682-10710
pubmed: 33980013
Mol Cell. 2014 Jan 23;53(2):247-61
pubmed: 24389101
J Med Chem. 2019 Dec 26;62(24):11232-11259
pubmed: 31724864
Nat Rev Cancer. 2021 Oct;21(10):638-654
pubmed: 34131295
Nat Genet. 2020 Dec;52(12):1384-1396
pubmed: 33139953
Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):12902-7
pubmed: 11687631
Cancers (Basel). 2021 Oct 11;13(20):
pubmed: 34680233
Nat Rev Drug Discov. 2019 Dec;18(12):949-963
pubmed: 31666732
J Med Chem. 2020 Jan 23;63(2):656-675
pubmed: 31858797
J Med Chem. 2020 Apr 23;63(8):4315-4333
pubmed: 32223236
Nat Struct Mol Biol. 2006 Sep;13(9):852-4
pubmed: 16892064
Nat Rev Cancer. 2015 Jun;15(6):334-46
pubmed: 25998713
Blood. 2019 Feb 28;133(9):952-961
pubmed: 30545835
ACS Chem Biol. 2018 Mar 16;13(3):553-560
pubmed: 29356495
Science. 2017 Mar 17;355(6330):1147-1152
pubmed: 28302822
Biochem J. 2013 Jan 1;449(1):151-9
pubmed: 22989411
EMBO J. 2001 Dec 17;20(24):7137-48
pubmed: 11742990
Nature. 2016 Jun 22;535(7611):252-7
pubmed: 27338790
J Am Chem Soc. 2013 Jan 16;135(2):669-82
pubmed: 23210835
J Biol Chem. 2008 Nov 21;283(47):32162-75
pubmed: 18829457
J Med Chem. 2016 Mar 24;59(6):2478-96
pubmed: 26958703
ACS Med Chem Lett. 2020 Mar 19;11(5):977-983
pubmed: 32435414
Sci Rep. 2018 Jan 22;8(1):1294
pubmed: 29358579
Cell. 2005 Jun 17;121(6):873-85
pubmed: 15960975
Mol Cell. 2015 May 7;58(3):440-52
pubmed: 25818646
Nat Chem Biol. 2017 May;13(5):514-521
pubmed: 28288108
J Biol Chem. 2012 Aug 10;287(33):27275-89
pubmed: 22665483
Cell Rep. 2019 Mar 12;26(11):2916-2928.e13
pubmed: 30865883
Oncotarget. 2016 Jun 21;7(25):37740-37754
pubmed: 27192115
Science. 2014 Jan 17;343(6168):305-9
pubmed: 24292623
Mol Cell. 2018 Oct 18;72(2):341-354.e6
pubmed: 30270106
Nat Rev Cancer. 2010 Jul;10(7):457-69
pubmed: 20574448
PLoS One. 2016 Nov 22;11(11):e0166438
pubmed: 27875550
J Biol Chem. 2008 Nov 21;283(47):32158-61
pubmed: 18829459
Nature. 2013 Jun 27;498(7455):516-20
pubmed: 23728302
Nat Commun. 2017 May 22;8:15398
pubmed: 28530236
J Med Chem. 2017 Jun 22;60(12):4818-4839
pubmed: 28603984

Auteurs

Dongxu Li (D)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Xufen Yu (X)

Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Jithesh Kottur (J)

Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Weida Gong (W)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Zhao Zhang (Z)

Department of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Aaron J Storey (AJ)

Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Yi-Hsuan Tsai (YH)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Hidetaka Uryu (H)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Yudao Shen (Y)

Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Stephanie D Byrum (SD)

Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Rick D Edmondson (RD)

Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Samuel G Mackintosh (SG)

Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Ling Cai (L)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Zhijie Liu (Z)

Department of Molecular Medicine, Mays Cancer Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.

Aneel K Aggarwal (AK)

Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Alan J Tackett (AJ)

Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Jing Liu (J)

Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Jian Jin (J)

Mount Sinai Center for Therapeutics Discovery, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jian.jin@mssm.edu.
Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. jian.jin@mssm.edu.

Gang Greg Wang (GG)

Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. greg_wang@med.unc.edu.
Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. greg_wang@med.unc.edu.
Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. greg_wang@med.unc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH